Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Editorial

Achieving LDL-cholesterol Targets: How Good are we in the Balkan Region?

Author(s): Djordje S. Popovic*, Edita Stokic, Anca Pantea Stoian and Nikolaos Papanas

Volume 20, Issue 4, 2022

Published on: 21 September, 2021

Page: [311 - 312] Pages: 2

DOI: 10.2174/1570161119666210921093735

Next »
[1]
Timmis A, Townsend N, Gale CP, et al. European Society of Cardiology: Cardiovascular Disease Statistics 2019. Eur Heart J 2020; 41: 12-85.
[2]
Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: A historical perspective. Lancet 2014; 383: 999-1008.
[3]
Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004; 364: 937-52.
[4]
Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell 2001; 104: 503-16.
[5]
Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-26.
[6]
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111-88.
[7]
De Backer G, Jankowski P, Kotseva K, et al. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis 2019; 285: 135-46.

© 2024 Bentham Science Publishers | Privacy Policy